赞助商


以下赞助商和合作伙伴给予BioBay创业投资论坛2009巨大的支持。我们衷心感谢这些一流机构和公司对本次论坛的大力协助。 

 主办方:

Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of successful initiatives connecting China biotech with the world. With offices in Shanghai, Silicon Valley and San Diego, our team of industry experts is truly Helping China biotech become global biotech™.
· Conferences: ChinaBio® organizes the premier investment and partnering forums in China
· Consulting: we help big pharma, entrepreneurs and investors achieve success in China
· Accelerator: our efforts have helped early stage companies raise over $60M US in China
· Research: we have unique, in-depth data on novel technology development, clinical trial activity, VC investment, M&A/IPO activity and partnering and collaboration deals in China
· ChinaBio® Today: our newsletter focusing exclusively on China’s life science industry. www.ChinaBioLLC.com.

 
Suzhou Industrial Park (SIP) Bio Bay is located in the southwest of SIP Dushu lake high education town. Suzhou Industrial Park, the biggest cooperation program between China and Singapore, is committed to develop into a high-tech industrial park with international competitiveness and a modern, international garden-like township. SIP Bio Bay plays a key role as the innovation base for Suzhou Industrial Park to cultivate biotechnology industry and also an innovation platform for the booming of biotechnology and nanotechnology development of both Suzhou city and China. www.biobay.com.cn/en/index.html

金牌赞助商:

 
Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry®, is the largest owner and preeminent real estate investment trust focused principally on cluster formation through the ownership, operation, management, selective redevelopment, development and acquisition of properties containing office/laboratory space. Alexandria provides high-quality environmentally sustainable real estate, technical infrastructure and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service, and translational entities, as well as government agencies. Alexandria extends its industry-leading operational platform into Asia with world-class office/laboratory space available for lease at its flagship development in Tianjin, China beginning in late 2009. www.labspace.com

 
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website:www.lifetechnologies.com
 
 
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. www.merck.com
 
 
Mingly China Growth Fund is a private equity fund formed in 2006 to make critical growth and expansion stage investments in China. The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals Demonstrated ability to identify sector leaders early and get closely engaged with founders Deep and growing pipeline with active processes to monitor companies, Hands-on operating experience to help transform companies, Global network of contacts to assist with technology, sales and marketing and management expertise, and Both Foreign Currency Fund and RMB Fund to meet the funding needs of various companies.www.mcgf.com.cn
 
 
From concept to commercialization and through exit, Morrison & Foerster's global Life Sciences Group is recognized as a leading provider of comprehensive legal services to the life sciences industry and its funding sources. The unique strength of our practice is in our ability to meld hands-on scientific acumen with deep business and legal insight. With offices in Shanghai, Beijing, and Hong Kong, as well as Tokyo, Europe and across the United States, Morrison & Foerster is incomparably positioned to assist life sciences entities around the world. For more information, please visit www.mofo.com.
 
 
Pfizer has been operating in China since the early 1980's committed to improving the health of the Chinese people and contributing to China's overall prosperity. Pfizer has built on this legacy by introducing innovative, relevant medicines and investing in doctor and patient educational programs. Furthermore, Pfizer contributes to China's scientific and medical development by including China in our global R&D projects. In recognition of the highly-skilled and talented scientists in China, Pfizer established its China Research and Development Center in Shanghai in 2005. The center is staffed with more than 200 Pfizer colleagues supporting various aspects of Pfizer's global R&D efforts.
www.pfizer.com
 
 
The Balloch Group ("TBG") was established in 2001 by Howard Balloch (Canada's ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008. TBG's professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside our clients in mergers and acquisitions, capital markets and direct investment transactions. www.ballochgroup.com
 
 
Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology and growth enterprises worldwide, as well as the investment banks and venture capital firms that finance them. Over the past four decades, Wilson Sonsini Goodrich & Rosati has established its reputation by having an unmatched knowledge of its clients' industries and deep and long-standing contacts throughout the technology sector.www.wsgr.com
 

银牌赞助商:

Broad & Bright is a full service Chinese law firm with international perspectives, providing a broad range of specialized legal services in multiple practice areas for domestic and international clients, with particular expertise and outstanding achievements in cross-border business transactions. Our Chinese and international educated lawyers have long term practice experience at Chinese and international law firms. www.broadbright.com

OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with over $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has created the first pan-Asia healthcare and life sciences-dedicated venture capital fund, with close to $200M under management. OrbiMed’s headquarters are in New York City and has offices in Shanghai and Mumbai. www.orbimed.com

晚宴赞助商:

 The Balloch Group ("TBG") was established in 2001 by Howard Balloch (Canada's ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008. TBG's professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside our clients in mergers and acquisitions, capital markets and direct investment transactions. www.ballochgroup.com
 
 

官方合作伙伴:
 
BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. www.bayhelix.org

BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 16 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange translational science joint publishing venture with Nature Publishing Group; and its BioCentury Extra online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence,an online business intelligence resource. www.biocentury.com


Business Wire is a trusted partner to thousands of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service.

Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. Business Wire is the only commercial news wire with full-carriage access to all of the world's leading news agencies, including the Associated Press, Agence France-Presse, Dow Jones, Reuters, Jiji Press, Interfax and more. We can send your news to virtually any media market in the world with distribution to more than 150 countries in dozens of local languages. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution. www.businesswire.com

 
 
goBalto is an online service that enables users to find, evaluate and manage drug development and manufacturing services providers such as Clinical Research Organizations ("CROs") and Contract Manufacturing Organizations ("CMOs") from all over the world (www.goBalto.com). Through our exclusive relationship with goBalto, ChinaBio has provided goBalto with our database of China-based CROs and CMOs. ChniaBio provides CRO/CMO selection and management services, to help companies ensure that they partner with a CRO/CMO that will meet their requirements and provide high quality data and product.
www.goBalto.com

 
Since 1969, Kidder Mathews has built a reputation of integrity and is known for focusing on delivering results that meet and often exceed client expectations. Over the years, Kidder Mathews has grown from a niche company to the acknowledged regional leader in providing a full spectrum of commercial real estate services. Services offered include brokerage, appraisal, property management, consulting, and project & construction management services. GVA Kidder Mathews facilitates $2.2 billion in commercial real estate transactions each year, and currently manages a property portfolio encompassing more than 22.6 million square feet. www.gvakm.com

风险投资合作伙伴:
 
Mingly China Growth Fund is a private equity fund formed in 2006 to make critical growth and expansion stage investments in China. The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals Demonstrated ability to identify sector leaders early and get closely engaged with founders Deep and growing pipeline with active processes to monitor companies, Hands-on operating experience to help transform companies, Global network of contacts to assist with technology, sales and marketing and management expertise, and Both Foreign Currency Fund and RMB Fund to meet the funding needs of various companies.www.mcgf.com.cn



Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. The Chan family founded the Hang Lung Group in Hong Kong in 1960. Morningside engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside was one of the earliest institutional investors in China's internet industry and in recent years has been a leader in China's emerging biotechnology sector. In China's media sector, Morningside has been active in both outdoor and print media.
www.morningside.com.cn
 
 
Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.

Lilly Ventures currently has $175 million under management and focuses on three major areas of interest.

Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline.

Medical Technology: targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics.

Healthcare IT: targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model.

Our investment approach centers on working with superior management teams to help them realize the financial potential of their ideas. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Our sister fund, Lilly Asian Ventures, was established in 2007 with a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India. www.lilly.com




In Chinese, “Qiming” literally means starting point and light, purporting the beginning of a new day. Headquartered in Shanghai, Qiming Ventures is dedicated to become a leading venture capital enterprise, devoting to the risk investment to Chinese scientific fields along with its American Ignition Partners. Currently, Qiming Ventures has over $500 million under management; together with its affiliate Ignition Partners, they manage more than $2.5 billion venture capital funds globally. Investment team of Qiming Ventures has rich expertise, enterprise operation practices and investment management experience at home and abroad; Qiming Ventures provides finance to experienced entrepreneurs and businesses with stable profit models, hoping to assist Chinese entrepreneurs to create enterprises with business volumes of billion US $.

Qiming Ventures is active to invest in the following sectors:
• HealthCare
• Media and Internet
• Information Technology
• Consumer and Retail
• Clean Energy
www.qimingventures.com


WI Harper Group works with entrepreneurs who target growth opportunities in Greater China as a key objective for their business. WI Harper pioneered the concept of building a business bridge across the Pacific Ocean for early stage IT and life sciences companies. Since 1996, we have backed over 90 emerging companies in China, Taiwan and the United States, resulting in 15 IPOs and a number of M&A transactions. Our investment professionals in Beijing, San Francisco and Taipei manage over $400M in assets. WI Harper currently manages six funds totaling over US$400 million from its headquarters in San Francisco and branch offices in Beijing, Taipei, and Singapore. WI Harper's portfolio includes over 90 companies in high-growth areas of information technology and life sciences. WI Harper's list of successful portfolio companies currently include examples such as Focus Media (NASDAQ: FMCN), ISSI (NASDAQ: ISSI), iKang, DivX (NASDAQ: DIVX), Commerce One, Bridge Pharmaceutical, Cardiva Medical, PC Home, Kuro, Silicon Motion (NASDAQ: SIMO), Beijing Xinwei, Verisilicon, China Broad Media, MAXTHON, HomeE, Panorama Stock, 3G Portal, Mapbar and Laszlo etc. The firm's previous investments include with companies such as Creative Technology, CommerceOne, Intraware, S3, ISSI and many other public companies.
www.wiharper.com



Mustang Ventures is a China-focused venture firm investing in early stage companies that leverage China’s large pool of intellectual talent, burgeoning domestic market, attractive cost structure, and / or proven export capability. Our team combines local investment experience, senior operating leadership and a global network that we leverage to help guide strong entrepreneurs to market success. Mustang’s partners bring together more than 40 years of operating experience and 10 years of investing experience. Our investing team is led by Rob McCormack, who has completed more than 25 investments in private companies while at Trident Capital and Integral Capital Partners, and our operating team by Leonard Liu, who brings more than 30 years experience in the IT industry, building teams and scaling operations at IBM, Acer, Cadence Design Systems, Walker Interactive Systems, ASE and Augmentum – three of which he grew to sales greater than $1 billion. Mustang has a strategic relationship with Trident Capital of Palo Alto, California. We work closely with our portfolio companies in all aspects of company building. From conceptualization of an idea to building a large and profitable business, we rely on our operational and investment expertise to work with entrepreneurs in building world class organizations. www.mustangvc.com



HBM BioMed China is a specialized venture capital organization dedicated exclusively to life sciences in China. Our main investments will be in China, or in multinational companies that have major operations within China. HBM BioMed China Limited is domiciled in the Cayman Islands and is advised by HBM BioMed China Partners, Hong Kong. HBM BioVentures, an internationally renowned Swiss life science focused holding company is the major shareholder of HBM Biomed China.
With all management team members based in mainland China, we are one of the first foreign venture capital organizations committed to take root in China’s Healthcare Industry. HBM BioMed China strives to generate long-term capital gains via investments in private companies within its target sectors human medicine, biotechnology and medical technology, as well as related industries. HBM BioMed China inherited the successful management model of HBM BioVentures in the hope of promoting China’s Healthcare Industry under its proactive collaboration and cooperation with other Chinese investment companies and cooperation with other Chinese investment companies and institutions. www.hbmbiomedchina.com



BioVeda invests in companies in the healthcare sector with leading market positions, proprietary technologies, and outstanding scientific and management talent. We are a crucial business and scientific bridge between companies in the East and West, linking business and technology between two very diverse markets.
Our experienced Investment Team and Advisory Board together provide a strong combination of broad scientific, industry and medical expertise, and financial and investment experience to assist partner companies.  www.bioveda.com.cn



Fidelity Asia Ventures (FAV) is the Asian venture capital arm of FIL Limited, part of the global Fidelity Investments organization. Fidelity Investments is one of the largest mutual fund organizations in the world, managing assets in excess of $1.5 trillion globally.
FAV's mission is to invest in high-quality, high-growth companies broadly in the information technology, healthcare, and consumer sectors in China. FAV has offices in Hong Kong, Beijing, and Shanghai, and a successful track record of investing in leading companies within their respective industries. Current investments and recent exits include: Alibaba (HKSE: 1688), AsiaInfo (NASDAQ: ASIA), Wuxi PharmaTech (NYSE: WX), Hurray! (NASDAQ: HRAY), Linktone (NASDAQ: LTON), Xunlei, and iSoftstone etc. For more information, please visit:  www.fidelityasiaventures.com



DFJ DragonFund is a leading venture capital firm in the People’s Republic of China. It is the exclusive China affiliate fund of the internationally recognized venture capital firm Draper Fisher Jurvetson (www.dfj.com). As a joint venture between DFJ and DragonVenture, DFJ DragonFund leverages an unparalleled track record of experience, knowledge, and success in venture capital both internationally and on the Chinese domestic and grass-roots level. At DFJ DragonFund, we focus on China-centric companies in the technology market. As an active early-stage investor, we work closely with companies in developing their business strategies. As a DFJ network affiliate, we also draw upon DFJ’s substantial resources and capabilities developed over two decades of venture capital investing. DFJ has an established presence in China technology investing, and is the only venture capital firm with a global presence through affiliates in more than 30 cities around the world and more than $3.5 billion in capital commitments. Prior to forming DFJ DragonFund, the members of our investment team managed several venture capital funds in the sector, and have completed numerous China-centric technology investments. The depth and breadth of our experience make DFJ Dragon a valuable partner in building successful businesses in the China technology markets. We welcome technologically diverse and financially ambitious projects. With our unique depth of experience, our team can add value and resources in a broad manner – from both local knowledge to strategic planning and execution throughout all stages of a company’s development. We focus on companies throughout a widely-defined technology arena.
Established in March of 2006, DFJ DragonFund is headquartered in Silicon Valley and maintains advisory offices in Beijing and Shanghai. www.dfjdragon.com

支持伙伴:


Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body set up by the Government of the Hong Kong SAR to promote and facilitate the transformation of Hong Kong into Asia’s hub for technology innovation. The Corporation supports a number of technology industries engaging in cutting-edge research and development, including the Life Science and Biotechnology industries, and offers a comprehensive range of facilities and services to address the needs of companies at various stages of development.
  www.hkstp.org

 
Shanghai Pudong Bio Industry Association (SPBIA), officially founded on September 12, 2002, is serving as a social group registered in Pudong New Area. According to “The Registration and Management Principal for Social Groups”, it will recruit voluntary members from enterprises, research institutes, colleges of medicine and individuals who works in bio-pharmaceutical industry. It is also the registered legal entity approved by the Bureau of Civil Administration of Pudong New Area. Its superior management unit is the Scientific and Technological Association of Pudong New Area.
 www.spbia.cn/english/index.asp
 
 
The Shanghai Pharma Engine has been largely responsible for the launch of the early stage biotech industry in Shanghai. They operate an incubator in the Zhangjiang Hi-Tech Park located next to ChinaBio's offices with 45 biotech startups housed in two buildings, and they are adding facilities for an additional 100 companies in the next year. The ChinaBio? Accelerator recently signed a collaboration agreement with the Pharma Engine where ChinaBio? will identify co-investment opportunities in the Park and Pudong New Area.www.pharma-engine.com/EN/
 
 
Beijing Pharma and Biotech Center (BPBC) is the principal health research agency of the Beijing Local Government; it is a component of Beijing Municipal Commission for Science and Technology (BMCST). Established in 1996 and initially function as the development and implementation of Beijing Government Grants Policy, BPBC serves as the focal point for advisory industrial policy, mandatory project management for government and international bridge between Chinese Biotech & Pharmaceutical Industry and the rest of the world. BPBC is composed of five divisions: Project Management, Strategy Study, Business Liaison and International Affairs, General Administration and Financial Management Divisions. www.newlife.org.cn/en
 
 
ChinaSF is an economic development platform supporting business exchange between China and San Francisco.  It is a partnership between the City of San Francisco Mayor's Office and the San Francisco Center for Economic Development.  With an office in Shanghai and in San Francisco, it is able to provide bi-lingual cross-border support to Chinese businesses interested in expanding business operations to North America.  In particular, it can connect Chinese businesses to necessary professional service resources, business partners and can help navigate government regulations.  This initiative builds on the already strong cultural exchange between San Francisco and China by providing a systematic support for strengthening business and economic relations.www.sfced.org/international/chinasf
 
 
BIOCOM is a leading biotechnology industry association with over 550 leading life science companies from Southern California as members. BIOCOM's initiatives focus on capital formation, public policy, resource development and scientific discovery and development. They have recently launched a special program to educate and connect U.S.-based life science companies with low cost resources and services available in China. www.biocom.org
 
 
Chinese-American BioPharmaceutical Society (CABS) is a not-for-profit, non-political, non-religious professional organization headquartered in San Francisco, California. With the rapid development of bio/pharmaceutical industry in China, more and more people, regardless of their ethnic backgrounds, are looking toward China for business and scientific opportunities. Recognizing this trend, CABS was established not only to educate the public with the progress in biotech and pharmaceutical fields, but also to serve the Bio/Pharmaceutical professionals who are either with Chinese heritage or with professional interests in China. The majority of CABS members are Chinese scientists, entrepreneurs and students/postdocs in biomedical sciences, working in San Francisco Bay Area bio/pharmaceutical industries, universities, and research institutes. The CABS membership is open to the public.
 
 
The Chinese Biopharmaceutical Association (CBA) is a non-profit organization made up of professionals who have an interest in bio-pharmaceutical research and/or technology development. CBA was established in 1995 and its headquarters are located in the State of Maryland, which is adjacent to the U.S. capital city of Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors. They work in government agencies, universities, research institutes as well as in the biotechnology and pharmaceutical industries. Some are conducting pioneering research with the National Institutes of Health (NIH), whereas others are directly involved in the government regulatory process as officers of the Food and Drug Administration (FDA) or in the field of intellectual property as patent attorneys or as patent examiners with the Patent and Trademark Office (PTO).http://www.cba-usa.org/cba_home.htm
 
 
Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA) is a 501(C) (3) nonprofit organization founded in early 2002 by professionals and scholars from local Chinese community in San Diego. We invite all scholars, students and professionals with any origin who are working in, engaged in, or interested in the biotech and pharmaceutical industry to join us as members of SABPA. www.sabpa.org/web/index.php
 
 
The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization with its headquarters in the Greater New York area (NJ/NY/CT). SAPA has grown rapidly to become one of the most active and well-recognized professional organizations in the United States with over 4000 members. SAPA's missions are to facilitate the advancement of pharmaceutical science and biotechnology, to contribute to public health education, to foster personal and professional career development, and to promote scientific exchange and business cooperation between the USA and China. In addition to the Greater New York area, SAPA has established regional chapters in New England (SAPA-NE), Greater Philadelphia (SAPA-GP) and West Coast (SAPA-WEST), as well as Shanghai Club (SAPA-Shanghai). www.sapaweb.org
 
 
Guangzhou Biotechnology Center (namely Biomedical work group of Guangzhou Municipal Government) under the jurisdiction of the Biotechnology Steering Group and the Sciences &Technology Bureau of Guangzhou Municipal Government is a service agency specializing in biotechnology and medicine industry. Its key missions are to develop the biotechnology and medicine industry of Guangzhou and to accelerate the transfer of S&T achievements and parallel cooperation and exchange. www.gzbio.net

 

媒体合作伙伴:

 
GB focuses exclusively on the pharmaceutical, healthcare, and biotechnology industries in China. With an understanding of ongoing policy shifts, a global perspective, and a granular knowledge of China’s players and practices, GB maintains a substantial advantage over diversified consulting firms. www.generalbiologic.com
 
 
生物谷创建于2001年,生物谷是目前国内最大的生物医药类门户网站。目前网站日点击量超过120万次,网站的综合国际排名高达5000位,始终保持在国内生物医药类网站的第一。生物在线提供生命科学领域的产品展示,企业展台,搜索排名,定向广告,品牌营销,EDM,数据库营销等提供相关的服务,已经成为在生命科学领域企业品 牌形象和产品宣传的必需站点,同时针对企业用户提供更为定向的营销模式。目前产品库中收录超过50万种产品(2008年1月数据),并快速增加,每天求购的用户超过20万人次(2008年1月数据)。
www.bioon.com
 
 
 PharmAsiaNews.com is an online portal providing news and analysis on regulatory, legal and financial developments affecting pharmaceutical, biologics and medical device manufacturers doing business in China, India, Japan and other nations of the Pacific Rim. PharmAsiaNews.com leverages the editorial excellence of "The Pink Sheet" -- the leading information source for the U.S. pharmaceutical industry since 1939. Subscribers get original on-the-ground reporting from news bureaus across Asia, guest columns, exclusive interviews, news summaries, English translation summaries of Chinese- and Japanese-language news, and aggregated content from around the globe. Free 30-day trial.
www.PharmAsiaNews.com
 
 
China Daily is one of the most authoritative providers of news and views in China. The paper has an average daily circulation of more than 300,000 in about 150 countries and regions. Two-thirds of China Daily’s worldwide readers are government officials, think-tanks and decision makers from multinational corporations. China Daily group has 11 English publications and one of the country’s top news internet portals. The website is one of the biggest English portals in Asia with more than 12 million daily hits, two-thirds of which are from overseas. China Daily’s Hong Kong edition is the only national publication in Hong Kong. 21st Century Weekly is the most-read English education weekly in China. A strategic cooperation agreement to open up China’s English educational market has been signed by China Daily and Scholastic Inc., the world’s largest publisher and distributor of children’s books. www.chinadaily.com.cn
 
 
China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of government and private investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotech companies and industry events, as well as global issues affecting the China market.  www.chinabiotoday.com



CRO Asia © is a premium online media platform targeting pharmaceutical outsourcing industry namely contract research and manufacturing organizations (CROs and CMOs) based in Asia-Pacific regions. CRO Asia's unique and innovative partnering approach is to present a wide variety of contract service providers in Asia-Pacific to a highly specialized audience of scientists, professionals and decision makers in pharmaceutical industry. Our objective is to forge potential collaborations and strategic partnerships between those two parties by using our unique marketing tools and quality communication services. www.croasia.net
 
 
 
Interfax China is a member of the Interfax International Information Group. Interfax Group provides news and other information products that are essential for decision-makers in politics and business. Since early 1990s, Interfax has been the main provider of up-to-date news from Russia and countries of the former Soviet Union. We are the most frequently quoted source of information on the region. Over the past few years, Interfax has also become a leading provider of political and business news from China and emerging markets of Central Europe.
www.interfax.cn

 

《医药经理人》(月刊)2008年12月正式创刊,以资深医药传媒人为基础团队,定位为“医药行业的新闻与资源中心”,核心读者群为医药企业经营者、投资者、医药行业监管与服务机构。主办单位是中国医药企业管理协会和卓信医学传媒集团。在内容制作上,把求实放在第一位,打通整个产业链条,挖掘药企经营者的经验与焦虑,战略与执行,成长与使命。形成中国医药行业最丰富的企业成长案例库。将国际视野和本土智慧有机结合,开放而聚焦,把对医药产业最丰富和深刻的理解带给读者,建立医药产业媒体新话语。把医药研发新产品、生产流通、产业监管与服务机构、资本等资讯第一时间放到行业高端媒体平台,形成信息对称,发现价值,共同成长。我们的愿景是每一位医药从业者手上都有一本《医药经理人》,我们现在要做的是每一期杂志都能给读者创造出一种兴奋感。
www.he-cn.com

 
VentureWire Lifescience is the venture industry’s premier source for comprehensive, accurate, daily intelligence on how health care-focused venture firms and their portfolio companies are gaining traction, creating value and finding exits in today’s complicated marketplace. Leveraging the global reporting acumen of Dow Jones, this extraordinary e-newsletter delivers right to your inbox every business morning:

Breaking News – Comprehensive news and analysis of pipeline developments, FDA rulings, licensing and partnership agreements, open and closed deals, and more.

Strategic Insights – FIRST notice of current deals, future financing plans, burn rates, valuations, forward market trends … days, even weeks, ahead of other sources (yes, even the free ones)!

In-Depth Trend Analysis – Exclusive reporting about what’s really happening—and why—with venture capital fund-raising, investment, liquidity, deal terms, compensation, and other key areas.

Personnel Updates – Advance warning of key executive moves, board-level changes, CEO hirings and firings, new partners and available positions. www.venturecapital.dowjones.com 

 

 
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. www.pharmaconnections.com

 

 


 

 

 

 
The Balloch Group ("TBG") was established in 2001 by Howard Balloch (Canada's ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008. TBG's professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside our clients in mergers and acquisitions, capital markets and direct investment transactions. www.ballochgroup.com

主办方

金牌赞助

银牌赞助

晚宴赞助

官方合作伙伴

VC合作伙伴

支持伙伴

媒体伙伴

ChinaBio® 会议

China Showcase 2020

美国,旧金山
2020年1月12号

ChinaBio 合作论坛2020

中国,苏州
2020年5月6-7号

合作伙伴会议